Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267773 | 0.90 | DAGLA (0.46) | TSPODAGLAALDH1A1TSHRUSP1 | |
| SCHEMBL10261859 | 0.84 | DAGLA (0.47) | TSPODAGLAALDH1A1TSHRMEN1 | |
| SCHEMBL10261340 | 0.84 | DAGLA (0.45) | TSPODAGLAALDH1A1TSHRMEN1 | |
| SCHEMBL10006781 | 0.82 | TSPO (0.40) | TSPOALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10261156 | 0.82 | TSPO (0.57) | TSPOALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10006652 | 0.81 | USP1 (0.39) | TSPODAGLAUSP1 | |
| SCHEMBL10261371 | 0.81 | TSPO (0.44) | TSPODAGLAALDH1A1KMT2AUSP1 | |
| SCHEMBL10008025 | 0.80 | USP1 (0.40) | TSPODAGLAALDH1A1TSHRMEN1 | |
| SCHEMBL10261397 | 0.79 | TSHR (0.41) | TSPOALDH1A1TSHRNPC1SMN1; SMN2 | |
| SCHEMBL10006624 | 0.79 | TSHR (0.43) | TSPOALDH1A1TSHRNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735406-B2 | 8-oxodihydropurine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172347-A1 | 8-OXODIHYDROPURINE DERIVATIVE | FAAH, FAAH2, TPMT | TSPO 1233/4885DAGLA 1038/4885ALDH1A1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.